R
Richard Fox
Researcher at University of Birmingham
Publications - 25
Citations - 3617
Richard Fox is an academic researcher from University of Birmingham. The author has contributed to research in topics: Sorafenib & Clinical trial. The author has an hindex of 15, co-authored 25 publications receiving 2410 citations. Previous affiliations of Richard Fox include University Hospitals Birmingham NHS Foundation Trust & University of Liverpool.
Papers
More filters
Journal ArticleDOI
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Philip J. Johnson,Sarah Berhane,Chiaki Kagebayashi,Shinji Satomura,M Teng,Helen L. Reeves,James O'Beirne,Richard Fox,Anna Skowronska,D. Palmer,Winnie Yeo,Frankie Mo,Paul B.S. Lai,Mercedes Iñarrairaegui,Stephen L. Chan,Bruno Sangro,Rebecca A. Miksad,Toshifumi Tada,Takashi Kumada,Hidenori Toyoda +19 more
TL;DR: The ALBI grade offers a simple, evidence-based, objective, and discriminatory method of assessing liver function in HCC that has been extensively tested in an international setting and eliminates the need for subjective variables such as ascites and encephalopathy, a requirement in the conventional C-P grade.
Journal ArticleDOI
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N. Primrose,Richard Fox,Daniel H. Palmer,Hassan Malik,Raj Prasad,Darius F. Mirza,Alan Anthony,Pippa Corrie,Stephen Falk,Meg Finch-Jones,Harpreet Wasan,Paul Ross,Lucy Wall,Jonathan Wadsley,Jeff Evans,Deborah D. Stocken,Raaj K. Praseedom,Yuk Ting Ma,Brian R. Davidson,John P. Neoptolemos,Timothy Iveson,James Raftery,Shihua Zhu,David Cunningham,O. James Garden,Clive Stubbs,Juan W. Valle,John Bridgewater +27 more
TL;DR: This randomised, controlled, multicentre, phase 3 study aimed to determine whether adjuvant capecitabine improved overall survival compared with observation following surgery for biliary tract cancer.
Journal ArticleDOI
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Tim Meyer,Tim Meyer,Richard Fox,Yuk Ting Ma,Paul Ross,Paul Ross,Martin W. James,Martin W. James,R Sturgess,Clive Stubbs,Deborah D. Stocken,Lucy Wall,A. Watkinson,Nigel Hacking,T.R. Jeffry Evans,Peter William Collins,Richard A Hubner,David Cunningham,John N. Primrose,Philip J. Johnson,Daniel H. Palmer,Daniel H. Palmer +21 more
TL;DR: In this paper, a multikinase inhibitor sorafenib was used to improve progression-free survival in patients with intermediate stage hepatocellular carcinoma compared to TACE with placebo.
Journal ArticleDOI
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.
L. Kadalayil,R. Benini,L Pallan,James O'Beirne,Laura Marelli,Dominic Yu,Allan Hackshaw,Richard Fox,Philip J. Johnson,A.K. Burroughs,Daniel H. Palmer,Tim Meyer +11 more
TL;DR: The HAP score predicts outcomes in patients with HCC undergoing TACE/TAE and may help guide treatment selection, allow stratification in clinical trials and facilitate meaningful comparisons across reported series.
Journal ArticleDOI
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
John N. Primrose,Richard Fox,Daniel H. Palmer,Raj Prasad,Darius F. Mirza,David Alan Anthoney,Philippa Corrie,Stephen Falk,Harpreet Wasan,Paul Ross,Lucy Wall,Jonathan Wadsley,T.R. Jeffry Evans,Deborah D. Stocken,Raaj K. Praseedom,David Cunningham,O. James Garden,Clive Stubbs,Juan W. Valle,John Bridgewater +19 more
TL;DR: BILCAP aimed to determine whether capecitabine (Cape) improves overall survival (OS) compared to observation (Obs) following radical surgery in the intention to treat (ITT) population.